Pfizer (PFE) Issues FY19 Earnings Guidance

Share on StockTwits

Pfizer (NYSE:PFE) issued an update on its FY19 earnings guidance on Tuesday morning. The company provided EPS guidance of $2.82-2.92 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.04. The company issued revenue guidance of $52-54 billion, compared to the consensus revenue estimate of $54.31 billion.Pfizer also updated its FY 2019 guidance to $2.82-2.92 EPS.

NYSE:PFE traded up $0.87 during trading hours on Thursday, reaching $42.45. The company’s stock had a trading volume of 38,505,206 shares, compared to its average volume of 26,304,212. The stock has a market capitalization of $242.70 billion, a PE ratio of 14.15, a P/E/G ratio of 2.10 and a beta of 0.87. Pfizer has a one year low of $33.20 and a one year high of $46.47. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.47.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 29th. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.63 by $0.01. The firm had revenue of $13.98 billion during the quarter, compared to analysts’ expectations of $13.92 billion. Pfizer had a net margin of 20.79% and a return on equity of 25.38%. Pfizer’s revenue for the quarter was up 2.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.62 earnings per share. On average, sell-side analysts forecast that Pfizer will post 2.88 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 1st. Stockholders of record on Friday, February 1st will be given a dividend of $0.36 per share. The ex-dividend date is Thursday, January 31st. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.39%. This is a positive change from Pfizer’s previous quarterly dividend of $0.34. Pfizer’s dividend payout ratio is currently 45.33%.

Pfizer declared that its Board of Directors has approved a share buyback plan on Friday, December 14th that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the biopharmaceutical company to reacquire up to 3.8% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its shares are undervalued.

A number of research analysts have recently commented on PFE shares. Independent Research set a $48.00 price objective on shares of Pfizer and gave the company a neutral rating in a research report on Thursday, October 4th. Cantor Fitzgerald set a $45.00 price target on shares of Pfizer and gave the stock a buy rating in a research note on Thursday, October 4th. Morningstar set a $46.00 price target on shares of Pfizer and gave the stock a neutral rating in a research note on Tuesday, October 9th. ValuEngine raised shares of Pfizer from a hold rating to a buy rating in a research note on Tuesday, October 9th. Finally, Credit Suisse Group set a $40.00 price target on shares of Pfizer and gave the stock a hold rating in a research note on Sunday, October 14th. Three analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus target price of $44.24.

A hedge fund recently raised its stake in Pfizer stock. Morgan Stanley lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 2.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 55,493,846 shares of the biopharmaceutical company’s stock after buying an additional 1,126,612 shares during the quarter. Pfizer makes up 0.6% of Morgan Stanley’s holdings, making the stock its 17th largest holding. Morgan Stanley owned about 0.93% of Pfizer worth $2,445,614,000 at the end of the most recent quarter. 69.16% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/4116093/pfizer-pfe-issues-fy19-earnings-guidance.html.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Further Reading: LIBOR

Earnings History and Estimates for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

AMETEK, Inc.  Shares Bought by Natixis Advisors L.P.
AMETEK, Inc. Shares Bought by Natixis Advisors L.P.
Corbus Pharmaceuticals  Coverage Initiated by Analysts at Oppenheimer
Corbus Pharmaceuticals Coverage Initiated by Analysts at Oppenheimer
CAI International  versus Fortress Transprtn and Infr Investrs  Head-To-Head Analysis
CAI International versus Fortress Transprtn and Infr Investrs Head-To-Head Analysis
Contrasting Red Lion Hotels  & Its Peers
Contrasting Red Lion Hotels & Its Peers
Takeda Pharmaceutical  Rating Reiterated by Goldman Sachs Group
Takeda Pharmaceutical Rating Reiterated by Goldman Sachs Group
Metlife  Lowered to Hold at Sandler O’Neill
Metlife Lowered to Hold at Sandler O’Neill


© 2006-2019 Ticker Report